Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered to discuss cutting-edge developments, and the Image of the Year was a novel peptide-based PET tracer targeting PD-L1 in head and neck cancers.
Sessions covered the latest in tracer development, theranostics, total-body PET, and AI-powered imaging strategies. The apparent excitement and rapid learning between established researchers and rising talent underscore how quickly the field is evolving.
These innovations are more than academic—they inform the development of better diagnostic tools and smarter clinical trial designs. Axcellant is excited to apply insights from SNMMI 2025 to strengthen our imaging‑focused clinical research services, helping advance patient care through precision and innovation.
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
The EU is moving forward with key upgrades to its medical device and diagnostics regulations, specifically under the Medical Device…
Copyright @ 2025 Axcellant